The purpose of this clinical trial is to learn more about a new, investigational, once daily medication, called baxdrostat, and its ability to lower blood pressure in individuals diagnosed with primary aldosteronism.
Eligible patients include those who currently have a diagnosis of high blood pressure, specifically primary aldosteronism, despite having taken or are currently taking anti-hypertensive medications.
